A series of retroviral vectors with potential anti-tat and anticonstructs inhibited virus replication at a high multiplicity of rev activity was developed. Vectors containing a tat transinfection (MOI). At a low MOI, two cell clones containing dominant negative mutant (tat 22/37 ) and an RRE decoy in tat 22/37 and the RRE decoy in 3′ position showed a long different positions, directed by the same promoter or by lasting protection against virus replication, in comparison different promoters, were generated. Retroviral vectors to control cultures expressing tat 22/37 or RRE alone. Combicontaining tat 22/37 and the RevM10 transdominant negative nation of tat and rev mutants was ineffective in inhibiting mutant were also constructed. Jurkat cells were trans-HIV-1 replication at both low and high MOIs. At a low MOI, duced with the recombinant retroviruses to produce mono-HIV-1 replication was efficiently blocked in two cell clones clonal and polyclonal cultures. In these cell lines the expressing the RevM10 mutant alone. These results show recombinant proviruses were correctly integrated and a synergic effect of anti-tat and anti-rev molecules when expression of the inserted genes was detected by Northern the RRE sequence is cloned 3′ to tat 22/37 , suggesting the blot or RT-PCR analysis. However, infection of these cell possibility of using this vector design to control HIV-1 lines with HIV-1 showed that none of these recombinant replication.
Introduction
fere with the virus lytic cycle. [11] [12] [13] [14] We have previously HIV-1 gene expression, during productive and chronic observed that Tat mutants in the transactivation domain infection, is essentially dependent upon the early regulat-(tat 22 and tat 22/37 ), where cysteines 22 and 37 were substiory genes tat and rev. After integration of the proviral tuted with glycine and serine, respectively, behave as DNA, the HIV-1 genome is transcribed into doubly transdominant negative mutants and control virus prospliced 2 kilobase pair (kbp) mRNAs encoding Tat, Rev duction during primary infection, using a low dose of and Nef proteins. Tat increases viral gene expression by input virus, and at reactivation of virus replication from binding to the transactivation responsive element (TAR), latency. [15] [16] [17] It has been suggested that the combination located at the 5′ end of all viral mRNAs, whereas Rev of two genes against different viral targets, including tat acts post-transcriptionally by binding to a cis-acting RNA and rev, may improve gene therapy against HIV-1, 10, [18] [19] [20] [21] [22] sequence, the Rev-responsive element (RRE). This internot only by a synergic effect between the single genes but action induces cytoplasmic accumulation of unspliced also by decreasing the probability of generating escape (9.0 kbp) or singly spliced (4.3 kbp) viral mRNAs, encomutants through a block in different steps of the virus ding the structural proteins, and therefore is required for life cycle. As an extension of our previous experiments, the synthesis of HIV-1 infectious particles. 1 The aim of in this study we have attempted to improve the antiviral somatic gene therapy for AIDS is the intracellular activity of tat 22/37 by associating this mutant with the RRE expression of an active antiviral gene which should lead decoy sequence or the RevM10 transdominant negative to resistance of uninfected cells against HIV-1 infection.
mutant. These types of recombinant molecules would On the other hand, intracellular immunization of infected have the advantage of combining a tat transdominant cells may inhibit virus replication and control virus reacmutant, that can inhibit intracellular and extracellular tivation from latency, thus preventing the spread of infecTat, with an anti-rev molecule which interferes with Rev tious virus. Tat and rev genes are considered very attractfunctions. Several recombinant retroviral vectors containive targets for antiviral gene therapy, 2, 3 since they play a ing the anti-tat and anti-rev genes in different combicritical role in the HIV-1 infectious cycle. Rev transdominations, directed by the same promoter or by different nant negative mutants were described 4, 5 and shown to promoters, were constructed. The pattern of integration suppress HIV-1 replication. [6] [7] [8] [9] [10] In addition, intracellular of these vectors and the expression of the exogenous genes was analysed and their antiviral activity was determined during HIV-1 infection of Jurkat T cells stably control the integration pattern of the proviruses ( Figure   Results 2, Table 1 (Figures 5a and 6b) . Conversely, the other anti-tat and anti-rev constructs containing the tat transdominant negative mutant in combination with the RRE decoy sequence (Ltat 22/37 CMVRRESN, LRREtat 22/37 SN, LRRECMVtat 22/37 SN) did not protect the cells against HIV-1 replication at both MOIs (not shown). In order to determine whether successful HIV-1 infection 
.8 kbp neo transcript is also indicated. Right panel. Lane 1, normal Jurkat cells; lane 2, J-LX cells; lane 3, J-LM10 polyclonal culture; lane 4, J-LM10 clone 1; lane 5, J-LM10 clone 2; lane 6, J-LM10 clone 3. The mRNAs of 3.5 and 4.1 kbp, directed from the MoMLV LTR in LXSN and LM10SN vectors, are indicated. The 1.8 kbp band corresponds to the neo transcript. (b) Ethidium bromide staining of the agarose-formaldehyde gels before Northern blot analysis. Samples are shown in the same order as in (a). The two bands corresponding to the 28S and 18S ribosomal RNAs are marked.

Figure 5 Susceptibility to HIV-1 strain HXBC2 infection of Jurkat polyclonal and monoclonal cell cultures stably transduced by Ltat 22/37 RRESN (a and b) and LM10SN retroviral vectors (c and d). MOIs of 1 IP/50 000 cells (a and c), or 1 IP/5000 cells (b and d) were used.
Ltat 22/37 SL3M10 containing tat 22/37 in combination with the tion. Tat 22/37 was linked to the RRE decoy sequence or to the RevM10 transdominant negative mutant. Several conRevM10 transdominant negative mutant showed that JLtat 22/37 SL3M10 cells were not resistant to HIV-1 challenge structs were made in the context of the LXSN vector, in order to assay the effect of tat 22/37 in the 5′ or 3′ position at a MOI of 1 IP/5000 and 1 IP/50 000 cells using the HXBC2 strain (not shown). We observed efficient protection with respect to the RRE or RevM10 sequence and to test the effect of the expression of both genes under control of against HIV-1 replication in two clones of Jurkat cells expressing the RevM10 transdominant negative mutant the same promoter or of different promoters. The results of these experiments indicate synergism of tat 22/37 and RRE. alone (J-LM10 clones 2 and 3) following infection with HXBC2 only at the MOI of 1 IP/50 000 cells (Figure 5c ).
This effect may involve binding of Rev to RRE, during replication of the challenging virus, thus increasing the amount These cultures, however, were not resistant to HXBC2 infection when a higher MOI of 1 IP/5000 cells was used (Figure of tat 22/37 RRE RNA that accumulates into the cytoplasm and is available for translation. Synergism was observed 5d). It is likely that the variation in the peaks of viral replication observed in different experiments depends on experionly when the RRE sequence is cloned 3′ to tat 22/37 and expression of both genes is driven by the MoMLV LTR. mental differences. Also the different RT peaks within the same experiments probably reflect the waves of virus repliThis effect may be due to steric hindrance on initiation of translation of tat 22/37 mRNA when the RRE decoy, whose cation in tissue culture, since similar replication patterns were described in previous studies. 7, 17, 18, 23, 24 RNA shows a highly convoluted conformation rich in secondary structures, is cloned 5′ to tat 22/37 .
The present results also indicate differences in the Discussion expression of the exogenous genes, as shown by Northern blot and RT-PCR analysis, among the J-Ltat 22/37 RRE We have previously observed that tat 22/37 behaves as a clones, which do not seem to correlate with the copy transdominant negative mutant in transient assays, number of the integrated provirus ( Figures 2-4 and Table  inhibits HIV-1 replication, protects Jurkat CD4 + T cells 1). Moreover, it was observed that protection against from HIV-1 lytic infection using a low MOI and controls HIV-1 infection is variable, even in cell clones where high virus reactivation from latency induced by TNF-␣ or steady-state RNA levels were consistently found. Indeed, superinfection with HHV-6. 17 In both situations (primary other investigators have reported variable gene infection with a low input virus and chronic infection), expression and antiviral activity of anti-HIV-1 recombiefficient competition by the Tat mutant was probably due nant molecules when using cell lines. 7, 13, 22, 25 These effects to the low amount of viral Tat protein, since at a higher are not completely understood and may reflect clonal dif-MOI tat 22/37 inhibited HIV-1 infection transiently and ferences in the cells induced by in vitro selection, differviral replication was resumed with time.
ences in the expression of the transgenes not detected by As an extension of this study we addressed the question RNA analysis or down-regulation of the expression of the of whether the antiviral activity of the tat 22/37 mutant could be improved by the contemporary inhibition of Rev funcexogenous genes during the infection by HIV-1. these situations, it may be necessary to develop an expression vector suitable for higher and stable expression of the anti-HIV molecules and to understand better the complex molecular mechanisms regulating HIV-1 This study also confirms that, as shown by others, 8, 10, 26 inhibition of HIV-1 replication in vitro by intracellular expression and interaction with the infected host. Peng et al 22 have recently shown that the antiviral activity of the immunization with antiviral genes is dependent on the amount of the challenging virus and is more effective at a same anti-tat and anti-rev antisense RNA is markedly different when expressed from retroviral vectors of different low MOI. These experiments and those reported by others [8] [9] [10] 26 also suggest that the expression level of the therapeutic design. Further studies are in progress to determine whether the anti-HIV-1 activity of tat 22/37 RRE can be genes may be the limiting factor for a successful control of HIV-1 replication by such approaches. The efficacy of improved by using an expression vector different from LXSN, such as the LNCX retroviral vector, 27 where the protection conferred by intracellular immunization against HIV-1 may depend on several factors, including the gene human cytomegalovirus early promoter is placed in the best position in order to obtain greater expression of the chosen as a target on the HIV-1 genome, the length and exogenous genes. Indeed, cells were more efficiently proPreparation of Jurkat T cell lines stably transduced with recombinant retroviral vectors tected against HIV-1 infection when the RevM10 mutant was expressed by the LNCX vector as compared to the The Jurkat T cell line, derived from a T cell lymphoma, was grown in RPMI 1640 medium containing 10% heat LXSN vector. 8 Further improvement will be attempted by reducing the size of the RRE sequence to avoid steric hininactivated fetal bovine serum. Monolayer cultures of PA317 amphotropic packaging cells were cultured in drance by the RRE RNA on translation of mRNA of the adjacent exogenous gene, based on the observation that a DMEM supplemented with 10% heat inactivated Hyclone serum (Hyclone Laboratories, Logan, UT, USA) and 1 × 13-nucleotide minimal RRE domain is sufficient to bind Rev and to establish a functional RRE decoy. 14 HAT components (100 m hypoxanthine, 0.4 m aminopterin, 16 m thymidine) (Gibco BRL, Grand Island, NY, In conclusion, the results of this study indicate that the combined expression of tat 22/37 and RRE has a synergic USA) in an atmosphere of 10% CO 2 . Monoclonal and polyclonal cultures of Jurkat cells stably transduced with action and does not affect cell growth, suggesting the possibility of using this association for an anti-HIV-1 the recombinant retroviruses were established as previously described. 17 Cell surface CD4 expression was therapy. These data also show that a combined anti-tat and anti-rev approach sometimes produces interference, monitored in all monoclonal and polyclonal cell lines by using flow cytometry as described. 15 A growth curve was since in some constructs tat 22 Polymerase chain reaction (PCR) amplification of tat, rev expression of tat 22/37 in J-Ltat 22/37 SL3M10. Therefore, introduction of an internal promoter in these recombiand RRE RNA was carried out as previously described 17 on total cytoplasmic RNA with previous reverse trannants is not an effective way to improve expression of the exogenous genes, perhaps depending on inhibition of scription into complementary DNA. PCR primers were:
(1) 5′GAAGAGCTCATCAGAACAGTCAGACT3′ (posretroviral vector sequences on the activity of the internal promoters. 22, 28 These observations may be relevant to the ition 5996-6021) and 5′ACCTTCTTCTTCTATTCCTTCG GG3′ (position 8434-8411), which allow amplification of development of recombinant molecules for intracellular immunization strategies against HIV-1. a 104 bp rev fragment; (2) 5′GAGCAGTGGGAATAGGA GCTTTGT3′ (position 7755-7778) and 5′AGGAGCTGTTG ATCCTTTAGGTAT3′ (position 8001-7978), which allow
Materials and methods
amplification of a 246 bp RRE fragment; and (3) 5′GAAG CATCCAGGAAGTCAGCC3′ (position 5862-5882) and Vector construction and generation of rev mutants The retroviral vector LXSN 27 was used to express anti-5′ACCTTCTTCTTCTATTCCTTCGGG3′ (position 8434-8411) for amplification of a 250 bp tat fragment. Amplifitat and anti-rev genes (Figure 1a-i ) Generation of the tat mutant, tat 22/37 , where cysteines at position 22 and 37 cation was carried out for 35 cycles at 95°C for 1 min, 50°C for 1 min, 72°C for 1 min. A second round of ampliwere substituted with glycine and serine and construction of plasmid Ltat 22/37 SN have been described elsefication was done at the annealing temperature of 55°C. PCR amplification for HIV-1 env proviral sequences was where.
17 To obtain the rev mutant RevM10, 4, 6 the SalIKpnI fragment of 778 bp, containing the two exons of the done on 1 g of cellular DNA using primers SK68 and SK69, 32 which produce a 141 bp env fragment, for 30 HIV-1 rev cDNA, was cloned into plasmid pTZ18U (USB, Cleveland, OH, USA) and site-directed mutagenesis was cycles (95°C for 1 min, 56°C for 1 min, 72°C for 1 min). All PCR reagents (dNTPs, reaction buffer and TaqI carried out, as described, 29 using a 31 base pair oligonucleotide (5′TCAGCTACCACCAGATCTCAGACTTAC polymerase) were provided by Boehringer Mannheim (Mannheim, Germany). Aliquots of each PCR reaction TCTT3′) with a GCT to AGA and a GAG to CTC mutation resulting in substitution of leucine 78 and gluwere migrated in 2% agarose gels and analysed by Southern blot hybridization. Rev, tat, neo and RRE DNA probes tamic acid 79 with aspartic acid and leucine, respectively. Sequence analysis of the mutant was carried out by the were labeled with 32 P by the random priming method, using the Rediprime labeling kit (Amersham). The SK70 chain termination reaction using the Sequenase version 2.0 kit (USB). Different promoters were used in the conoligonucleotide env DNA probe 32 was labeled at the 5′ end with T4 polynucleotide kinase. 31 Probe concenstructs to direct tat 22/37 , RevM10, the RRE sequence and the neo genes: the endogenous LTR of LXSN retroviral trations of 1 × 10 6 c.p.m./ml were used for hybridization reactions. vector, the simian virus 40 (SV40) early promoter, the human cytomegalovirus (CMV) immediate-early promoter (from plasmid pRc/CMV, Invitrogen, San Diego, HIV-1 infection HIV-1 strains HXBC2 and NL4.3 were used in these CA, USA) and the SL3 LTR promoter, derived from the SL3 murine leukemia virus. 30 Specific details on vector experiments. Virus stocks were produced and titrated as described. 15,17 They had a titer of 1.25 × 10 5 TCID 50 /ml constructions are available from the authors.
